(154) Nasal-to-brain Approach: lipid-coated Clozapine Albumin Nanoparticles for Treatment of Schizophrenia
Introduction: Clozapine is a BCS class II drug with low solubility and high permeability. However, low oral bioavailability ( < 27%) and severe adverse drug reactions make clozapine conventional therapy limited for preferable use. At nasal pH, it remains ionized, resulting in rapid mucociliary clearance and poor absorption. The albumin nanoparticles can entrap the drug to improve penetration of clozapine from the olfactory region. Stearylamine, a cationic lipid, was coated to extend the drug's residence period in the nasal cavity due to its electrostatic interactions with negatively charged epithelial cells.
Learning Objectives:
to learn the nose-to-brain route improves the availability of clozapine in the brain.
Learn that designed delivery reduce adverse effect on peripheral tissues delivering the drug to CNS.
The participant will learn about formulation and characterization of lipid-coated albumin delivery
